Safety Study of SD-101 (a Novel C Type TLR9 Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
This study has been completed.
Sponsor:
Dynavax Technologies Corporation
Collaborators:
Synteract, Inc.
PPD
Information provided by:
Dynavax Technologies Corporation
ClinicalTrials.gov Identifier:
NCT00823862
First received: January 14, 2009
Last updated: February 9, 2010
Last verified: February 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | February 2010 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |